Evidence map›Paper›PMID 38946881›Full record

ArticleNeuro-oncology advances

Survival after resection of malignant peripheral nerve sheath tumors: Introducing and validating a novel type-specific prognostic model.

Ibtissam Acem, Ewout W Steyerberg, Marta Spreafico, Dirk J Grünhagen, Dario Callegaro, Robert J Spinner, Courtney Pendleton, J Henk Coert, Rosalba Miceli, Giulia Abruzzese and 17 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ibtissam AcemDepartment of Surgical Oncology and Gastrointestinal Surgery,Erasmus MC Cancer Institute, >Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-8042-9856
Ewout W SteyerbergDepartment of Biomedical Data Sciences, Leiden University Medical Centre, >Leiden, The Netherlands.
Marta SpreaficoDepartment of Medical Statistics, Mathematical Institute, Leiden University, >Leiden, The Netherlands.
Dirk J GrünhagenDepartment of Surgical Oncology and Gastrointestinal Surgery,Erasmus MC Cancer Institute, >Rotterdam, The Netherlands.
Dario CallegaroDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, >Milan, Italy.
Robert J SpinnerDepartment of Neurosurgery, Mayo Clinic, >Rochester, Minnesota, USA.
Courtney PendletonDepartment of Neurosurgery, Stony Brook University School of Medicine, Stony Brook, New York, USA.
J Henk CoertDepartment of Reconstructive Surgery, University Medical Centre Utrecht, >Utrecht, The Netherlands.
Rosalba MiceliDepartment of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, >Milan, Italy.
Giulia AbruzzeseDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, >Milan, Italy.
Uta E FluckeDepartment of Pathology, Radboud University Medical Centre, >Nijmegen, The Netherlands.
Willem-Bart M SlooffDepartment of Neurosurgery, University Medical Centre Utrecht, >Utrecht, The Netherlands.
Thijs van DalenDepartment of Surgical Oncology and Gastrointestinal Surgery,Erasmus MC Cancer Institute, >Rotterdam, The Netherlands.
Lukas B BeenDepartment of Surgical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Han J BonenkampDepartment of Surgical Oncology, Radboud University Medical Centre, >Nijmegen, The Netherlands.
Monique H M E AntenDepartment of Neurology, Maastricht University Medical Centre, >Maastricht, The Netherlands.
Martinus P G BroenDepartment of Neurology, Maastricht University Medical Centre, >Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-8834-2202
Marc H A BemelmansDepartment of Surgical Oncology, Maastricht University Medical Centre, >Maastricht, The Netherlands.
Jos A M BramerDepartment of Orthopedic Surgery, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Gerard R SchaapDepartment of Orthopedic Surgery, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Arthur J KievitDepartment of Orthopedic Surgery, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Jos van der HageDepartment of Surgical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Winan J van HoudtDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michiel A J van de SandeDepartment of Orthopedic Oncology, Leiden University Medical Centre, >Leiden, The Netherlands.
Alessandro GronchiDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, >Milan, Italy.ORCID https://orcid.org/0000-0002-4703-3534
Cornelis VerhoefDepartment of Surgical Oncology and Gastrointestinal Surgery,Erasmus MC Cancer Institute, >Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9980-8613
Enrico MartinDepartment of Reconstructive Surgery, University Medical Centre Utrecht, >Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to assess the performance of currently available risk calculators in a cohort of patients with malignant peripheral nerve sheath tumors (MPNST) and to create an MPNST-specific prognostic model including type-specific predictors for overall survival (OS). Methods: This is a retrospective multicenter cohort study of patients with MPNST from 11 secondary or tertiary centers in The Netherlands, Italy and the United States of America. All patients diagnosed with primary MPNST who underwent macroscopically complete surgical resection from 2000 to 2019 were included in this study. A multivariable Cox proportional hazard model for OS was estimated with prespecified predictors (age, grade, size, NF-1 status, triton status, depth, tumor location, and surgical margin). Model performance was assessed for the Sarculator and PERSARC calculators by examining discrimination (C-index) and calibration (calibration plots and observed-expected statistic; O/E-statistic). Internal-external cross-validation by different regions was performed to evaluate the generalizability of the model. Results: A total of 507 patients with primary MPNSTs were included from 11 centers in 7 regions. During follow-up (median 8.7 years), 211 patients died. The C-index was 0.60 (95% CI 0.53-0.67) for both Sarculator and PERSARC. The MPNST-specific model had a pooled C-index of 0.69 (95%CI 0.65-0.73) at validation, with adequate discrimination and calibration across regions. Conclusions: The MPNST-specific MONACO model can be used to predict 3-, 5-, and 10-year OS in patients with primary MPNST who underwent macroscopically complete surgical resection. Further validation may refine the model to inform patients and physicians on prognosis and support them in shared decision-making.

Indexed as

internal–external validationmalignant peripheral nerve sheath tumorsmodel performanceneurofibromatosis 1prognosis

Identifiers

PMID38946881
PMCPMC11212065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.